Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence

Enarodustat, a newly developed hypoxia‐inducible factor prolyl hydroxylase inhibitor, is used in clinical practice in Japan. Several clinical studies showed that enarodustat corrected and maintained hemoglobin (Hb) levels by stimulating endogenous erythropoietin production and improving iron utiliza...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Therapeutic apheresis and dialysis 2022-08, Vol.26 (4), p.679-693
Hauptverfasser:	Fujikawa, Ryo, Nagao, Yuji, Fujioka, Masaki, Akizawa, Tadao
Format:	Artikel
Sprache:	eng
Schlagworte:	anemia in chronic kidney disease enarodustat erythropoietin HIF‐PH inhibitor iron utilization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!